Background: Transient hyperglycemia is seen commonly during TB treatment, yet its association with unfavorable treatment outcomes is unclear.
Research Question: Does an association exist between glycated hemoglobin (HbA1c) trajectories and TB treatment outcomes?
Study Design And Methods: Adults with pulmonary TB were evaluated prospectively for 18 months after the second HbA1c measurement. HbA1c trajectories during the initial 3 months of treatment were defined as follows: persistent euglycemia, HbA1c < 6.5% at baseline and 3-month follow-up; persistent hyperglycemia, HbA1c ≥ 6.5% at baseline and 3-month follow-up; transient hyperglycemia, HbA1c ≥ 6.5% at baseline and < 6.5% at 3-month follow-up; incident hyperglycemia, HbA1c < 6.5% at baseline and ≥ 6.5% at 3-month follow-up. Multivariable Poisson regression was used to measure the association between HbA1c trajectories and unfavorable treatment outcomes of failure, recurrence, and all-cause mortality.
Results: Of the 587 participants, 443 participants (76%) had persistent euglycemia, 118 participants (20%) had persistent hyperglycemia, and 26 participants (4%) had transient hyperglycemia. One participant had incident hyperglycemia and was excluded. Compared with participants with persistent euglycemia, those with transient hyperglycemia showed a twofold higher risk of experiencing an unfavorable treatment outcome (adjusted incidence rate ratio [aIRR], 2.07; 95% CI, 1.04-4.15) after adjusting for confounders including diabetes treatment, and BMI; we did not find a significant association with persistent hyperglycemia (aIRR, 1.64; 95% CI, 0.71-3.79). Diabetes treatment was associated with a significantly lower risk of unfavorable treatment outcomes (aIRR, 0.38; 95% CI, 0.15-0.95).
Interpretation: Transient hyperglycemia and lack of diabetes treatment was associated with a higher risk of unfavorable treatment outcomes in adults with pulmonary TB.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10851276 | PMC |
http://dx.doi.org/10.1016/j.chest.2023.08.026 | DOI Listing |
Anticancer Agents Med Chem
January 2025
Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Lung cancer is correlated with a high death rate, with approximately 1.8 million mortality cases reported worldwide in 2022. Despite development in the control of lung cancer, most cases are detected at higher stages with short survival rates.
View Article and Find Full Text PDFCurr Protein Pept Sci
January 2025
Dr. Zafar H. Zaidi Center for Proteomics, University of Karachi, Karachi-75270, Pakistan.
Background: Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer with a high recurrence rate. A new therapeutic intervention is urgently needed to combat this lethal subtype. The identification of biomarkers is also crucial for improving outcomes in TNBC.
View Article and Find Full Text PDFCurr Rheumatol Rev
January 2025
University of Toronto, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada.
Psoriatic arthritis (PsA) is a heterogeneous inflammatory disease with various joint and skin manifestations and multiple associated comorbidities. The management of PsA is important not only in controlling disease activity and preventing subsequent damage but also in improving the quality of life and reducing mortality. Over the years, numerous drugs have been introduced into the therapeutic armamentarium of the disease.
View Article and Find Full Text PDFCurr Pharm Des
January 2025
Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Intrauterine Adhesions (IUA) are a significant cause of infertility and miscarriage, often resulting from trauma to the endometrium. While hysteroscopic adhesiolysis is the primary treatment, the use of hydrogels as anti-adhesion barriers and drug delivery systems is gaining traction for improving patient outcomes. This review aims to explore various hydrogel types, their role in tissue repair, and the integration of stem cell therapy.
View Article and Find Full Text PDFHealth Econ
January 2025
School of International Trade and Economics, University of International Business and Economics, Beijing, China.
While the direct health impacts of air pollution are widely discussed, its indirect effects, particularly during pandemics, are less explored. Utilizing detailed individual-level data from all designated hospitals in Wuhan during the initial COVID-19 outbreak, we examine the impact of air pollution exposure on treatment costs and health outcomes for COVID-19 patients. Our findings reveal that patients exposed more intensively to air pollution, identified by their residence in downwind areas of high-polluting enterprises, not only had worsened health outcomes but also consumed more medical resources.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!